Cocooning: A concept to protect young children from infectious diseases

Current Opinion in Pediatrics

Volumn 24, Issue 1, 2012, Pages 92-97

  Grizas, Alexandra P ^a   Camenga, Deepa ^a   Vázquez, Marietta ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cocooning; influenza; maternal vaccination; pertussis

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE;

CHILD CARE; CHILD HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; INFECTION; INFLUENZA; OUTCOME ASSESSMENT; PERTUSSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VACCINATION;

CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; WHOOPING COUGH;

EID: 84856103393     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834e8fe9     Document Type: Review

References (48)

1. Forsyth KD, Wirsing von Konig CH, Tan T, et al. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007; 25:2634-2642. (Pubitemid 46400927)
2. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004; 22:3154-3165. (Pubitemid 39037219)
3. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13-15. This guideline outlines the current ACIP recommendations for Tdap cocooning and provides a review of published and unpublished data that support the administration of Tdap to older adults.
4. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190:335-340. (Pubitemid 38951975)
5. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:1-100.
6. Liang J. ACIP Working Group. Update on pertussis in the United States; 2010. http://www.cdc.gov/vaccines/recs/acip/slides-feb11.htm#pertussis. [Accessed 25 September 2011]
7. Cortese MM, Baughman AL, Zhang R, et al. Pertussis hospitalizations among infants in the United States, 1993 to 2004. Pediatrics 2008; 121:484-492.
8. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988; 296:612-614. (Pubitemid 18059445)
9. Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24:S58-S61. (Pubitemid 40676539)
10. Tindberg Y, Blennow M, Granstrom M. A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J 1999; 18:361-365. (Pubitemid 29183322)
11. Lugauer S, Heininger U, Cherry JD, et al. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002; 161:142-146. (Pubitemid 34169862)
12. Mertsola J, Viljanen MK, Ruuskanen O. Current status of pertussis and pertussis vaccination in Finland. Ann Clin Res 1982; 14:253-259. (Pubitemid 13172733)
13. Nelson JD. The changing epidemiology of pertussis in young infants: the role of adults as reservoirs of infection. Am J Dis Child 1978; 132:371-373. (Pubitemid 9129606)
14. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293-299. (Pubitemid 46596651)
15. Hanson MP, Kwan-Gett TS, Baer A, et al. Infant pertussis epidemiology and implications for tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination: King County, Washington, 2002 through 2007. Arch Pediatr Adolesc Med 2011; 165:647-652. This study describes a retrospective analysis of reported cases of pertussis among infants less than 1 year old which describes the suspected exposure location for these infant patients.
16. He Q, Viljanen MK, Nikkari S, et al.Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 1994; 170:873-877. (Pubitemid 24296565)
17. Srugo I, Benilevi D, Madeb R, et al. Pertussis infection in fully vaccinated children in day-care centers, Israel. Emerg Infect Dis 2000; 6:526-529.
18. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Science 2010; 330:982-985.
19. Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992; 14:708-719.
20. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55:1-37.
21. Advisory Committee on Immunization Practices (ACIP). ACIP provisional recommendations for pregnant women on use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap). 2011. http:// www.cdc.gov/vaccines/recs/provisional/default.htm. [Accessed 19 September 2011]
22. World Health Organization (WHO). Pertussis vaccines: WHOposition paper - recommendations. Vaccine 2011; 29:2355-2356. This study outlines the WHO position statement on pertussis cocooning and highlights the lack of evidence in this field.
23. Centers for Disease Control and Prevention (CDC). Tetanus and pertussis vaccination coverage among adults aged >/18 years: United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1302-1306. This report describes the recent Tdap vaccination coverage rates in the United States. Importantly, it highlights that the US population is not well vaccinated against pertussis.
24. Miller BL, Kretsinger K, Euler GL, et al. Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) among adults: United States, 2005-2007. Vaccine 2011; 29:3850-3856. This study demonstrates that US adults are generally willing to receive the Tdap vaccine, which suggests that low Tdap vaccination rates may be due to lack of access or ineffective vaccine delivery systems rather than patient refusal.
25. Healy CM, Rench MA, Baker CJ. Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis 2011; 52:157-162. This study describes the development and evaluation of a successful postpartum cocooning program and outlines the challenges with implementation. This program has been highlighted as a successful example of cocooning in the midst of skepticism over the scalability and sustainability of cocooning programs.
26. Walter EB, Allred N, Rowe-West B, et al. Cocooning infants: Tdap immunization for new parents in the pediatric office. Acad Pediatr 2009; 9:344-347.
27. Dylag AM, Shah SI. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit. Pediatrics 2008; 122:e550-e555.
28. Healy CM, Rench MA, Castagnini LA, et al. Pertussis immunization in a highrisk postpartum population. Vaccine 2009; 27:5599-5602.
29. Centers for Disease Control and Prevention (CDC). Progress in immunization information systems: United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:133-135. This describes how well immunization information systems (computerized information systems for vaccination tracking) track vaccinations for adults and children.
30. Westra TA, de Vries R, Tamminga JJ, et al. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 2010; 32:1479-1495. This is a recent cost-effectiveness analysis of cocooning in the Netherlands, a country with similar pertussis incidence rates to the United States.
31. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342:225-231. (Pubitemid 30058953)
32. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1-52.
33. Shah SI, Turcotte F, Meng HD. Influenza vaccination rates of expectant parents with neonatal intensive care admission. J Matern Fetal Neonatal Med 2008; 21:752-757.
34. Munoz FM. Vaccination during pregnancy. Womens Health (Lond Engl) 2007; 3:227-241. (Pubitemid 46488184)
35. World Health Organization (WHO). Global Programme for Vaccines and Immunization. Programme Report 1995. WHO/GVP/96.01; 1996.
36. Kohler PF, Farr RS. Elevation of cord over maternal IgG immunoglobulin: evidence for an active placental IgG transport. Nature 1966; 210:1070-1071.
37. Hobbs JR, Davis JA. Serum gamma-G-globulin levels and gestational age in premature babies. Lancet 1967; 1:757-759.
38. Reuman PD, Paganini CM, Ayoub EM, et al. Maternal-infant transfer of influenza-specific immunity in the mouse. J Immunol 1983; 130:932-936. (Pubitemid 13186331)
39. Mbawuike IN, Six HR, Cate TR, et al. Vaccination with inactivated influenza A virus during pregnancy protects neonatal mice against lethal challenge by influenza A viruses representing three subtypes. J Virol 1990; 64:1370-1374. (Pubitemid 20087783)
40. Benowitz I, Esposito DB, Gracey KD, et al. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 2010; 51:1355-1361. This study demonstrates the effectiveness of influenza vaccine when given to pregnant women in preventing hospitalization of their infants for influenza in the first 6 months of life.
41. Centers for Disease Control and Prevention (CDC). National, state, and urban area vaccination coverage among children aged 19-35 months: United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:988-993.
42. Centers for Disease Control and Prevention (CDC). Pertussis (whooping cough). 2011. http://www.cdc.gov/pertussis/fast-facts.html. [Accessed 15 September 2011]
43. Centers for Disease Control and Prevention (CDC). Where has all the pertussis gone? Pertussis trends from 1990-2008 and the potential early impact of Tdap vaccination. In: Proceedings of the 43rd National Immunization Conference; 30 March - 2 April 2009; Sheraton Hotel, Dallas, Texas.
44. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed. Washington, DC: Public Health Foundation; 2011. pp. 215-232.
45. Centers for Disease Control and Prevention (CDC). Children: the flu, and the flu vaccine. 2011. http://www.cdc.gov/flu/protect/children.htm. [Accessed 27 September 2011]
46. Coudeville L, van Rie A, Andre P. Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies. Epidemiol Infect 2008; 136: 604-620. (Pubitemid 351472170)
47. US Department of Health and Human Services. Healthy people 2020. Immunization and infectious diseases. Objective IID-1.6. Healthy People 2020; US Department of Health and Human Services, Office of Disease Prevention and Health Promotion; ODPHP publication no. B0132. November 2010.
48. Burke BL Jr, Nesmith CC, Ott RE, et al. Through with the flu: how free family and caregiver immunization protects sick neonates. Clin Pediatr 2010; 49:20-23.